Phase II study of irinotecan (cpt-11) and cisplatin (cddp) regimen (IP) with concurrent thoracic radiotherapy (TRT) in limited-stage small cell lung cancer (LS-SCLC) ...

Q4 2025 earnings call: nimacimab + semaglutide data, higher-dose expansion, Halozyme SC plans, 2026 catalysts—read now.

I’ve had countless skin issues over the years, and I’m no stranger to the seemingly never-ending cycle of spending money on remedies, products and treatments, only to have so many of them not work for ...

Clinton County Emergency Services Director James King was in Elizabethtown on Monday to talk to the Essex County Board of ...

CFN’s 2026 college football spring rankings continue with teams 51-100, including rising programs, transfer portal impact, ...

Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

CRANFORD, N.J., March 10, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology?focused biopharmaceutical company and majority?owned subsidiary of Citius ...

Real-world community study finds Enhertu in HER2-low metastatic breast cancer has trial-like discontinuation rates; ILD remains key toxicity.

Plus a First Look at their “Spa in the Sky” amenities program Aero Extends Weekly Flights to Maui Through Summer Aero Extends Weekly Flights to Maui Through Summer LOS ANGELES, March 05, 2026 (GLOBE ...

Proper Hospitality has introduced an extensive range of wellness programmes and retreats at two of its properties, including ...

A real-world study found rates of toxicity-related T-DXd discontinuation in HER2-low metastatic breast cancer similar to those observed in DESTINY-Breast04. A real-world cohort of patients with ...